drugset / Trial / NCT03367559
Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam
Phase 3
Unknown
360 enrolled
Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Bharat Biotech International Limited · collab
NaSingle-groupOpen-labelPrevention
Summary
An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated oral rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam.
Timeline
- Start
- 2018-02-08
- Primary completion
- 2019-05
- Completion
- 2019-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROTAVAC® | Vaccine | — | Oral |